ReviewJournal of fungi (Basel, Switzerland)2023
Clinical Features and Treatment Progress of Invasive Mucormycosis in Patients with Hematological Malignancies.
Review in Journal of fungi (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Pooled it
- Clinical characteristics and risk factors for mortality in pulmonary mucormycosis among patients with non-hematologic malignancies.BMC pulmonary medicine · 2026Article
- Review
- Review
- Early Antifungal Treatment in Immunocompromised Patients, Including Hematological and Critically Ill Patients.Journal of fungi (Basel, Switzerland) · 2026Review
- Rapid Diagnosis of Mucor and Aspergillus Co-Infection by Direct Microscopic Examination: A Case Report and Literature Review.Infection and drug resistance · 2026Article
- A Rare Case ofInfectious disease reports · 2025Article
- Clinical characteristics of tracheobronchial mucormycosis: a retrospective analysis of twenty cases.Annals of medicine · 2025Article
- A clinical presentation of rhino-orbito-cerebral mucormycosis in a patient with aplastic anemia: a case report.Journal of medical case reports · 2025Article
- Case Report: Immune checkpoint inhibitor exhibits dual benefits for a refractory lymphoma patient with disseminated mucormycosis.Frontiers in medicine · 2025Article
- Epidemiology, Clinical, Radiological and Biological Characteristics, and Outcomes of Mucormycosis: A Retrospective Study at a French University Hospital.Journal of fungi (Basel, Switzerland) · 2024Article
- Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.Annals of medicine · 2024Review
- Impact of SARS-CoV-2 on Viral Respiratory Infections in Patients with Hematological Malignancies.Viruses · 2024Article
- [Analysis of clinical characteristics and risk factors of death in critical burn patients complicated with invasive fungal infection].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2023Article
- Overcoming the Odds: Successful Treatment of Disseminated Mucormycosis with Gastrointestinal and Jaw Involvement in a Patient with Acute Myeloid Leukemia.Case reports in infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The incidence rate of invasive mucormycosis (IM) in patients with hematological malignancies (HMs) is increasing year by year, ranging from 0.07% to 4.29%, and the mortality rate is mostly higher than 50%. With the ongoing pandemic of COVID-19, COVID-19-associated mucormycosis (CAM) also became a global health threat. Patients with high risk factors such as active HMs, relapsed/refractory leukemia, prolonged neutropenia may still develop breakthrough mucormycosis (BT-MCR) even under the prophylaxis of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.